Cue Health Inc.

NasdaqCM:HLTH Stock Report

Market Cap: US$14.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Cue Health Future Growth

Future criteria checks 2/6

Cue Health is forecast to grow earnings and revenue by 51% and 38.4% per annum respectively. EPS is expected to grow by 68.7% per annum. Return on equity is forecast to be -46% in 3 years.

Key information

51.0%

Earnings growth rate

68.71%

EPS growth rate

Medical Equipment earnings growth16.5%
Revenue growth rate38.4%
Future return on equity-45.99%
Analyst coverage

Low

Last updated10 Apr 2024

Recent future growth updates

Recent updates

Analysis Article May 10

Take Care Before Jumping Onto Cue Health Inc. (NASDAQ:HLTH) Even Though It's 26% Cheaper

Unfortunately for some shareholders, the Cue Health Inc. ( NASDAQ:HLTH ) share price has dived 26% in the last thirty...
Analysis Article Mar 22

Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 26%

Unfortunately for some shareholders, the Cue Health Inc. ( NASDAQ:HLTH ) share price has dived 26% in the last thirty...
Analysis Article Jan 28

Cue Health Inc.'s (NASDAQ:HLTH) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Cue Health Inc. ( NASDAQ:HLTH ) shareholders are no doubt pleased to see that the share price has bounced 31% in the...
Analysis Article Jan 06

We're A Little Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article Nov 10

Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 28%

Cue Health Inc. ( NASDAQ:HLTH ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article Aug 14

These Analysts Think Cue Health Inc.'s (NASDAQ:HLTH) Sales Are Under Threat

The analysts covering Cue Health Inc. ( NASDAQ:HLTH ) delivered a dose of negativity to shareholders today, by making a...
Analysis Article Jul 12

Can Cue Health (NASDAQ:HLTH) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article May 15

Revenue Downgrade: Here's What Analysts Forecast For Cue Health Inc. (NASDAQ:HLTH)

The latest analyst coverage could presage a bad day for Cue Health Inc. ( NASDAQ:HLTH ), with the analysts making...
Analysis Article Mar 21

Cue Health Inc. (NASDAQ:HLTH) Analysts Just Slashed This Year's Revenue Estimates By 56%

The latest analyst coverage could presage a bad day for Cue Health Inc. ( NASDAQ:HLTH ), with the analysts making...
Analysis Article Mar 12

We Think Cue Health (NASDAQ:HLTH) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article Feb 13

Cue Health Inc.'s (NASDAQ:HLTH) Intrinsic Value Is Potentially 44% Above Its Share Price

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Cue Health Inc...
Analysis Article Nov 18

Cue Health Inc. (NASDAQ:HLTH) Analysts Just Trimmed Their Revenue Forecasts By 24%

Market forces rained on the parade of Cue Health Inc. ( NASDAQ:HLTH ) shareholders today, when the analysts downgraded...
Analysis Article Oct 30

Here's Why We're Not Too Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha Oct 04

Cue Health applies for FDA emergency use nod for its flu & COVID-19 molecular test

Cue Health (NASDAQ:HLTH) on Tuesday said it had applied to the U.S. FDA for an emergency use approval for its flu and COVID-19 diagnostic test. The Cue Flu + COVID-19 Molecular Test is for use at home and for point of care use, delivering results to mobile devices in 25 minutes, the company said in a statement. The test can differentiate between flu and COVID-19 strains, and if approved will be integrated into the company's health app. Cue's standalone molecular tests for both flu and COVID-19 are currently under de novo review with the FDA for full clearance. HLTH stock +2.8% to $3.12 in morning trading.
Seeking Alpha Sep 08

Cue Health appoints chief medical oficer

Cue Health (NASDAQ:HLTH) has appointed David Tsay, MD, PhD, as its Chief Medical Officer.  Dr. Tsay comes to Cue with more than 20 years of experience in clinical medicine, research, and health technology. Most recently, Dr. Tsay served at Apple, where he led an Apple Health clinical team in developing new Health products, including FDA-cleared products in cardiovascular health. As CMO, Dr. Tsay will help define future Cue diagnostic products and services.

Earnings and Revenue Growth Forecasts

NasdaqCM:HLTH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026207-44N/AN/A2
12/31/2025110-170N/AN/A3
12/31/202457-224N/AN/A3
12/31/202371-373-158-138N/A
9/30/2023199-257-189-161N/A
6/30/2023251-276-231-188N/A
3/31/2023329-291-255-197N/A
12/31/2022483-194-175-112N/A
9/30/2022529-138-142-51N/A
6/30/2022683-67-838N/A
3/31/202273334-4157N/A
12/31/202161833-125-9N/A
9/30/2021439-11-16134N/A
6/30/2021220-24-6076N/A
3/31/202187-37-4465N/A
12/31/202023-471593N/A
12/31/20197-21-16-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLTH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HLTH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HLTH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HLTH's revenue (38.4% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: HLTH's revenue (38.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HLTH is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/28 11:44
End of Day Share Price 2024/05/28 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cue Health Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Matthew SykesGoldman Sachs
Tejas SavantMorgan Stanley